Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Radioactive Iodine-refractory Differentiated Thyroid Cancer”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Early research (Phase 1)Study completedNCT01413113
What this trial is testing

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Who this might be right for
Recurrent Thyroid CancerStage IVA Follicular Thyroid CancerStage IVA Papillary Thyroid Cancer+4 more
University of Washington 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT04560127
What this trial is testing

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

Who this might be right for
Radioactive Iodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital 20
Testing effectiveness (Phase 2)Study completedNCT03244956
What this trial is testing

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

Who this might be right for
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
Gustave Roussy, Cancer Campus, Grand Paris 40
Testing effectiveness (Phase 2)Study completedNCT02390934
What this trial is testing

Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer

Who this might be right for
Thyroid Cancer
Gustave Roussy, Cancer Campus, Grand Paris 13
Large-scale testing (Phase 3)UnknownNCT03048877
What this trial is testing

Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Peking Union Medical College Hospital 118
Testing effectiveness (Phase 2)Active Not RecruitingNCT05660954
What this trial is testing

Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Who this might be right for
Differentiated Thyroid Cancer
Grupo Espanol de Tumores Neuroendocrinos 41
Testing effectiveness (Phase 2)UnknownNCT04554680
What this trial is testing

Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

Who this might be right for
Thyroid Cancer
National University Hospital, Singapore 5
Testing effectiveness (Phase 2)Looking for participantsNCT06970353
What this trial is testing

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

Who this might be right for
Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationAdvanced PDTC or ATC With NRAS Mutation
Fudan University 40
Not applicableStudy completedNCT02764554
What this trial is testing

Post-Marketing Surveillance of Lenvima in Korean Patients

Who this might be right for
Differentiated Thyroid Carcinoma (DTC)
Eisai Korea Inc. 132
Not applicableStudy completedNCT02303444
What this trial is testing

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

Who this might be right for
Thyroid Neoplasms
Bayer 667